Chiesi satsar på leverinriktad genterapi

Läkemedelsbolaget Chiesi tar ytterligare kliv in på genterapiområdet genom ett licensavtal med amerikanska Arbor Biotechnologies.

ZEISS Hosts an exceptional Global Conference on Innovation and Production in Berlin

More than 50 distinguished speakers from leading manufacturing companies.

“Conducting research at universities is becoming more and more like working at a research hotel”

The government wants Swedish research to focus on excellence and innovation, but can the two be combined? Life Science Sweden talks to Anna Falk, a professor at...

Revealing the secrets of a part

CT inspection in automation technology at Festo.

Controlled Pneumatics: pushing the boundaries of pneumatics

Pressure, flow rate and movement can now be controlled very precisely, and with exactly the energy actually required. Controlled Pneumatics is the combination o...

Efter förseningen – nu lämnar Xspray in uppdaterad FDA-ansökan

Forskningsbolaget Xspray Pharma har nu lämnat in en uppdaterad FDA-ansökan om godkännande för leukemibehandlingen Dasynoc.

The future of healthcare in focus: ”Together, things happen”

In march, it’s once again time for Fokus Patient, an event for the industry where the patients’ perspective takes center stage. It’s a great way to spread knowl...

Medivir CEO on upcoming study: ”It's about working together with others”

Medivir is a small company with a big task: to take its drug candidate, via extensive clinical studies, all the way to a patient group that currently lacks appr...

Klartecken för Pharmnovo – kan gå vidare med studie i nervsmärta

Pharmnovo har fått godkännande från spanska myndigheter att genomföra en fas IIa-studie för att pröva bolagets läkemedelskandidat för behandling av neuropatisk smärta.

High-tech companies are increasingly focusing on health

Tech companies have been taking an interest in healthcare for many years, and this interest seems to be increasing. “It’s not a sudden shift in trend, it’s more...

Health politician Lina Nordquist: ”I find it hard to be idle”

She is the pharmacist and researcher who grew tired of the breakthroughs that never materialised and knowledge that never seemed to reach patients, so she decid...

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)

Karolinska ska bli ett europeiskt powerhouse för ATMP

Karolinska ATMP-centrum har ett enkelt men ambitiöst syfte: korta vägen mellan akademisk upptäckt och klinisk tillämpning. ”Vi önskar att Karolinska i framtiden...

Även Sanofi pausar brittiska investeringar

Sanofi går i flera andra läkemedelsjättars fotspår och fryser alla investeringsbeslut om forskning och utveckling i Storbritannien.

Affibody AB

Anna Törner: Yes, I Am Sick, But Not Weak

”People often say that someone who is ill only has one wish—to get better. But I think that is not true. Someone who is ill also longs to be understood, to be r...

Improved processes and more

Discover the full potential and benefits.

The race between new alzheimer’s drugs Kisunla and Leqembi heats up

Kisunla or Leqembi? The rivalry between Eli Lilly and Bioarctic is intensifying. Where one drug gains approval, the other falls behind. Here's a look at the mar...

Discover Precision: Join ZEISS at the Control Fair in Stuttgart

May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.

The dock that “thinks” for itself

The world of bulk material handling seems straightforward at first glance: moving, filling, delivering. However, the art of dealing with a variety of different ...

Milstolpe nådd för Leqembi – Bioarctic kan casha in

Försäljningen av alzheimerläkemedlet Leqembi har nått sin första milstolpe, och därmed kan svenska Bioarctic på allvar börja skörda frukterna av sitt utvecklingsarbete.

The Top 10 Challenges Facing Laboratories Today

Navigating the Laboratory Automation Landscape

Alzinova tar steg mot fas II-studie i USA

Biofarmabolaget Alzinova hoppas kunna inleda en fas II-studie med sin vaccinkandidat mot Alzheimers under andra halvåret 2025.

Bico säljer bolag inom in vitro-testning och digital patologi

Bioteknikbolaget Bico avyttrar Mattek och Visikol, som integrerades i Mattek operationellt förra året, till Sartorius Lab. Köpeskillingen är på 80 miljoner doll...